The 
Introduction
Epidemiological studies have shown that lower serum levels of vitamin D 3 are associated with increased risk of prostate, colon, and breast cancer (Garland et al., 2009) . The biological activities of vitamin D 3 are attributed to 1␣, 25(OH) 2 D 3 ], which acts primarily by binding to the vitamin D receptor (VDR) (Deeb et al., 2007) . 1␣,25(OH) 2 D 3 shows antiproliferative, prodifferentiation, and antiangiogenic effects in both human prostate cancer cells in vitro and preclinical animal studies (Deeb et al., 2007) . In addition, preliminary clinical investigations have reported a promising antitumor role of 1␣,25(OH) 2 D 3 . For example, cotreatment of advanced prostate cancer patients with taxanes (e.g., paclitaxel, docetaxel) and 1␣,25(OH) 2 D 3 was shown to potentiate cytotoxic effects and/or increase the survival rates compared with treatment with only taxanes or placebo (Muindi et al., 2002; Beer et al., 2007) . In addition, AIDS patients have lower vitamin D 3 levels (Dao et al., 2011) , which may render them susceptible to further lowering of immune function, bone diseases, and increased risk of opportunistic infections. Vitamin D 3 and its derivatives have been successfully used in the treatment of autoimmune skin diseases such as psoriasis and vitiligo (Sigmon et al., 2009) .
In vertebrates, vitamin D 3 is synthesized from 7-dehydrocholesterol in the skin through exposure to UVB radiation or can be obtained from dietary sources (Deeb et al., 2007) . Serum proteins transport vitamin D 3 to the liver, where multiple cytochrome P450 (P450) enzymes in mitochondria (e.g., CYP27A1) and microsomes (e.g., CYP2J3 and CYP2R1) are capable of hydroxylating it at the C-25 position (Prosser and Jones, 2004; Ingraham et al., 2008) . The serum 25(OH)D 3 has gained some acceptance as a measure of vitamin D 3 in the body (Schuster, 2011) . In response to low calcium levels, renal CYP27B1 catalyzes the 1␣-hydroxylation of 25(OH)D 3 to form 1␣,25(OH) 2 D 3 , which is a small lipophilic molecule with superior cellular penetration and is the most potent endogenous agonist of VDR (Ingraham et al., 2008) . Subsequently, 1␣,25(OH) 2 D 3 is converted to inactive metabolites by mitochondrial CYP24A1 in kidney (Schuster, 2011) .
Epidemiological and clinical reports show that patients on certain classes of medications, such as antiepileptics (e.g., carbamazepine and phenytoin) and protease inhibitors (e.g., efavirenz), experience lower vitamin D 3 levels, altered calcium metabolism, and impaired bone health (Verrotti et al., 2010) . Likewise, vitamin D deficiency-like bone-related problems (e.g., bone fracture and osteonecrosis) were observed in patients who received dexamethasone, a commonly used anti-inflammatory glucocorticoid steroid and often used as a premedication for taxane-based chemotherapy of advanced cancers (Hussain et al., 2005; Beer et al., 2007) or as a single agent in acute lymphoblastic leukemia (Inaba and Pui, 2010) . Treatment of infant pigs with dexamethasone led to lower 1␣,25(OH) 2 D 3 levels, reduced calcium absorption, and impaired bone metabolism (Weiler et al., 1995) . In contrast, prednisone, which is also an anti-inflammatory glucocorticoid steroid with adverse effects on bone health (Reid and Heap, 1990) , is less potent than dexamethasone in repressing markers for bone formation (e.g., osteocalcin) as well as overall bone health (e.g., bone fracture, osteopenia, osteonecrosis) (Dubois et al., 2003; Inaba and Pui, 2010) . There is no experimental evidence to define the effects of glucocorticoids on biotransformation of biologically active 1␣,25(OH) 2 D 3 . In addition, a lack of studies present challenges for the direct comparison of dexamethasone-and prednisone-mediated negative effects on vitamin D 3 status and bone health.
1␣,25(OH) 2 D 3 works as a paracrine and as an autocrine agent via VDR-mediated mechanisms (Morris and Anderson, 2010) . Thus, catabolism of 1␣,25(OH) 2 D 3 in the liver could have a significant impact on VDR response. CYP3A4 is the major hepatic phase I oxidative drug-metabolizing enzyme with broad substrate specificity and is inducible after exposure to therapeutic, dietary, and environmental agents (Thummel and Wilkinson, 1998) . Gupta et al. (2004 Gupta et al. ( , 2005 reported that CYP3A4 mediates 24-and 25-hydroxylation activity of 1␣(OH)D 3 , but not vitamin D 3 , in human liver microsomes (HLM). Hepatic biotransformation of 1␣,25(OH) 2 D 3 by P450 enzymes may influence its circulating serum and tissue levels. Xu et al. (2006) reported on the hepatic metabolism of 1␣,25(OH) 2 D 3 in humans; however, there is no report of 1␣,25(OH) 2 D 3 biotransformation in mice, despite the fact that it is a widely used animal model in vitamin D research. Our study investigates the comparative biotransformation of 1␣,25(OH) 2 D 3 to its inactive hydroxy metabolites in mouse liver microsomes (MLM) and HLM. In addition, we have sought to determine the effects of various medications, which are commonly used in the treatment regimens of patients with cancer (e.g., ketoconazole, tamoxifen, taxanes), AIDS (e.g., ritonavir, clarithromycin), as well as inflammatory disorders (e.g., dexamethasone, prednisone), on hepatic biotransformation of 1␣,25(OH) 2 D 3 .
Materials and Methods
Chemicals. 1␣,25(OH) 2 D 3 , 25(OH)D 3 , dexamethasone sodium, prednisone, ␣-naphthoflavone, furafylline, sulfaphenazole, 8-methoxypsoralen, orphenadrine, quinine, 2-diethylaminoethyl 2,2-diphenylvalerate hydrochloride (SKF 525A), sodium diethyldithiocarbamate, docetaxel, paclitaxel, chloramphenicol, and clarithromycin were obtained from Sigma-Aldrich Canada Ltd. (Oakville, ON, Canada). Ritonavir and troleandomycin were purchased from Toronto Research Chemicals (North York, ON, Canada) and Enzo Life Sciences International, Inc. (Plymouth Meeting, PA), respectively. Ketoconazole and tamoxifen were obtained from MP Biomedical, LLC (Solon, OH). Pooled HLM of mixed gender were purchased from XenoTech, LLC (Lenexa, KS).
Baculovirus-insect cell control microsomes (no cytochrome b 5 or reductase), insect cells coexpressed with P450 reductase and cytochrome b 5 , and baculovirus insect cell microsomes containing human CYP3A4 enzyme coexpressed with P450 reductase and human cytochrome b 5 (BD Supersomes Enzymes) were purchased from BD Biosciences (Oakville, ON, Canada). NADPHregenerating solutions (A and B) were obtained from BD Gentest (Woburn, MA). Triazolam and its authentic metabolites were purchased from Cerilliant Corporation (Round Rock, TX). 5-Bromo-4-chloro-3-indolyl phosphate ptoluidine salt and nitro blue tetrazolium were purchased from Fisher Scientific (Ottawa, ON, Canada). Goat polyclonal anti-mouse CYP3A IgG and rabbit polyclonal anti-GAPDH serum were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA) and Novus Biologicals (Littleton, CO), respectively. Alkaline phosphatase-conjugated swine anti-goat IgG and goat anti-rabbit IgG secondary antibodies were purchased from Cedarlane Laboratories (Burlington, ON, Canada) and Jackson ImmunoResearch Laboratories Inc. (West Grove, PA), respectively. All other chemicals were obtained from commercial sources.
Animal Treatment and Preparation of Liver Microsomes. Adult male CD-1 mice were obtained from Harlan Laboratories Inc. (Montreal, QC, Canada). Mice were housed in polycarbonate cages with corn-cob bedding at a temperature of 20 -23°C and had a 12-h photoperiod. Mice were given commercial mouse diet and water ad libitum. Mice were cared for and treated in accordance with the principles and guidelines of the Canadian Council on Animal Care.
Mice were treated with dexamethasone or prednisone dissolved in 50% ethanol at a dosage of 80 mg/kg b.wt. or an equivalent volume of vehicle (three mice per group) by intraperitoneal injection once a day, for three consecutive days. Mice were euthanized 24 h after the last dose, and livers were immediately excised and were used for preparation of microsomes by differential ultracentrifugation. Microsomal pellets were suspended in 0.25 M sucrose, and aliquots were stored at Ϫ80°C until needed. Total protein concentration in each microsomal sample was determined by the bicinchoninic acid (Thermo Fisher Scientific, Waltham, MA) assay using bovine serum albumin as the protein standard.
1␣,25(OH) 2 D 3 Biotransformation Assay. In vitro reaction mixtures contained 100 mM potassium phosphate buffer (pH 7.4), mouse hepatic microsomal protein (0.15 mg/ml) or human hepatic microsomal protein (0.25 mg/ ml), or human recombinant CYP3A4 (rCYP3A4) Supersomes (15 pmol/ml), NADPH-regenerating system (solution A and B), and varying concentrations of 1␣,25(OH) 2 D 3 (2-40 M) in a final volume of 0.3 ml. A fixed concentration of 20 M 1␣,25(OH) 2 D 3 was used to compare the treated samples, and this concentration was also used in the inhibition studies. For the substrate depletion study, 1␣,25(OH) 2 D 3 was incubated with hepatic microsomes from vehicle-, dexamethasone-, or prednisone-treated mice at a concentration of 1 M. After an initial preincubation at 37°C for 10 min, the reaction was initiated by adding saturating concentrations of NADPH and was allowed to proceed for 30 min in a shaking water bath. The reaction was terminated with 900 l of ice-cold acetonitrile. Protopanaxatriol (0.5 g/ml) was used as an internal standard in the assay. Tubes were vortex-mixed for 1 min and centrifuged at 12,000 rpm for 5 min at 4°C. Supernatant was transferred to a clean Eppendorf tube and dried down using a CentriVap centrifugal evaporation system (35°C). Samples were then reconstituted in 100 l of methanol, and an aliquot was injected into the liquid chromatography/mass spectrometry (LC/MS).
The assay conditions were optimized to ensure that product formation was linear with respect to amount of protein and incubation time. Appropriate controls, including samples without substrate, microsomes or NADPH, were routinely used in the assay. For the study using human rCYP3A4, control samples contained insect cell microsomes or P450 reductase (plus cytochrome b 5 ) microsomes instead of CYP3A4 protein.
A Waters Acquity ultraperformance liquid chromatography (UPLC) system (Waters, Milford, MA) coupled to a Quattro Premier XE (Waters) triple quadrupole mass spectrometer (MS) was used for analysis of hydroxy metabolite formation of 1␣,25(OH) 2 D 3 and substrate depletion. Chromatographic separations of hydroxy metabolites of 1␣,25(OH) 2 D 3 were performed on a Waters Acquity UPLC BEH C18 column (2.1 ϫ 100 mm, 1.7 M) at 40°C with a flow rate maintained at 0.3 ml/min and total run time of 20 min. The mobile phase consisted of solvent A (water/2 mM ammonium acetate/0.1% 908 DEB ET AL.
at ASPET Journals on November 6, 2017 dmd.aspetjournals.org formic acid) and solvent B (methanol/2 mM ammonium acetate/0.1% formic acid) with the following conditions: 50% methanol (0 -0.2 min), followed by a gradient of 50 -100% methanol (0.2-15 min), isocratic elution with 100% methanol (12-20 min), and finally 50% methanol (17-20 min Chemical Inhibition Studies. P450 inhibitors were added into the incubation mixture containing 1␣,25(OH) 2 D 3 and hepatic microsomes from vehicle-, dexamethasone-, or prednisone-treated mice containing an NADPH-regenerating system as described under Chemicals. The P450 inhibitors and their concentrations were selected on the basis of previous reports and are as follows:
, and orphenadrine (200 M) (Newton et al., 1995; Zhang et al., 2007) . Reactions were initiated with NADPH after initial preincubation of MLM with 1␣,25(OH) 2 D 3 and the P450 inhibitor for 10 min at 37°C. For the mechanism-based inhibitors (furafylline, 8-methoxypsoralen, orphenadrine, diethyldithiocarbamate, and SKF 525A), preincubation was performed with all incubation constituents at 37°C for 15 min before the reaction was initiated by addition of 1␣,25(OH) 2 D 3 .
Inhibition Study with Commonly Used Drugs and Determination of IC 50 Value. Ketoconazole, tamoxifen, docetaxel, paclitaxel, ritonavir, clarithromycin, troleandomycin, and chloramphenicol were coincubated with HLM and 1␣,25(OH) 2 D 3 , and the reaction was allowed to proceed as described under 1␣,25(OH) 2 D 3 Biotransformation Assay. Drugs were preincubated with HLM and 1␣,25(OH) 2 D 3 for 10 min at 37°C followed by initiation of the reaction by adding NADPH. Ritonavir, tamoxifen, troleandomycin, and clarithromycin (mechanism-based inhibitors) were preincubated at 37°C for 20 min with HLM and NADPH, and the reaction was initiated by addition of 1␣,25(OH) 2 D 3 . Varying concentrations of ketoconazole (0.05-10 M), ritonavir (0.05-10 M), tamoxifen (1-100 M), docetaxel (0.1-1.24 M), and clarithromycin (1-100 M) were used to determine the IC 50 values of these drugs for inhibition of 1␣,25(OH) 2 D 3 biotransformation in HLM. The CYP3A inhibitory potential of these drugs was evaluated by triazolam hydroxylation assay after coincubation in HLM and human rCYP3A4 Supersomes.
Gel Electrophoresis and Western Blot Analysis. CYP3A protein levels were measured in mouse hepatic microsomal samples by immunoblot analysis. GAPDH protein levels were measured in the same samples as a loading control. Microsomal proteins were resolved by 7.5% SDS-polyacrylamide gel electrophoresis and were electrophoretically transferred onto nitrocellulose membranes. Membranes were incubated with goat polyclonal anti-mouse CYP3A IgG (1:100 dilution) or rabbit polyclonal anti-GAPDH serum (1:100 dilution) overnight at 4°C, followed by a 2-h incubation with alkaline phosphatase-conjugated swine anti-goat IgG or with goat anti-rabbit IgG at a dilution of 1:3000. Immunoreactive CYP3A and GAPDH protein bands were visualized by alkaline phosphatase-based colorimetric detection, and densitometric analyses were performed with GeneTools Software (Syngene Inc., Frederick, MD). Relative CYP3A protein levels in microsomes are expressed as the ratio of the intensity of the CYP3A band to that of the GAPDH band.
Human and Mouse CYP3A Marker Activity Assay. Hydroxylation of triazolam to 1Ј-hydroxy triazolam and 4-hydroxy triazolam was used as a marker for the activity of mouse and human CYP3A enzymes. In vitro reaction mixtures contained 100 mM potassium phosphate buffer (pH 7.4), mouse hepatic microsomal protein (0.3 mg/ml) or human hepatic microsomal protein (0.5 mg/ml), NADPH-regenerating system, and triazolam (243 M for mouse microsomes or 50 M for human microsomes) in a final volume of 0.150 ml incubated for 20 min at 37°C. The reaction was terminated with 450 l of ice-cold acetonitrile. 1Ј-Hydroxytriazolam-d 4 (0.2 g/ml) was used as an internal standard in the assay. Tubes were vortex-mixed for 1 min and centrifuged at 12,000 rpm for 5 min at 4°C. Supernatant was transferred to a clean Eppendorf tube, and an aliquot was directly injected into the LC/MS for quantification of 1Ј-hydroxy triazolam and 4-hydroxy triazolam. Hydroxy metabolites of triazolam were separated on a Waters Acquity UPLC BEH C18 column (2.1 ϫ 100 mm, 1.7 M) at 35°C with a flow rate maintained at 0.3 ml/min and total run time of 5 min. The mobile phase consisted of solvent A (water/0.1% formic acid) and solvent B (acetonitrile/0.1% formic acid) with the following conditions: 50% acetonitrile (0 -0.2 min), followed by a gradient of 50 to 100% acetonitrile (0.2-2 min), isocratic elution with 100% acetonitrile (2-3 min), and finally 50% acetonitrile (3-5 min). The LC eluant was introduced into the MS, and all data were collected in electrospray ionization positive mode with a capillary voltage of 3 kV. Source and desolvation temperatures were 120°C and 300°C, respectively, and N 2 gas flow was 900 l/h. MassLynx version 4.1 software was used for data acquisition and Quantlynx analyses. The quantitative determination of 1Ј-hydroxy triazolam and 4-hydroxy triazolam was performed by multiple reaction monitoring of the m/z 359 Ͼ 176 (cone voltage, 40 V; collision energy, 27 eV) and 359 Ͼ 314 (cone voltage, 35 V; collision energy, 27 eV) transitions, respectively.
Statistical Analysis. Parametric tests were used when the data passed the normality and equal variance test. Nonparametric tests were used when the data failed to pass the normality test and equal variance test (SigmaStat Statistical Software, version 3.1; SPSS Inc., Chicago, IL). Differences between mean values of two treatment groups were analyzed using the Student's t test (parametric), and when there were more than two treatment groups, the data were analyzed by one-way analysis of variance (parametric) or Kruskal-Wallis one-way analysis of variance test (nonparametric), followed by Student Newman Keuls multiple comparison test (SigmaStat Statistical Software, version 3.1). The level of significance was set a priori at P Ͻ 0.05. IC 50 values were determined by nonlinear regression analysis using GraphPad Prism 5 (GraphPad Software Inc., San Diego, CA). The IC 50 value data are expressed as means with associated 95% confidence limits in parenthesis. (Fig. 1A) . In the present experimental conditions, metabolites eluted between 8.5 to 9.7 min. The internal standard and substrate eluted at 8.8 and 10.9 min, respectively. Metabolite peaks corresponding to 1␣,23S,25(OH) 3 D 3 (M1) and 1␣,24R,25(OH) 3 D 3 (M2) were eluted at 8.5 and 8.8 min, respectively (Supplemental Fig. 1 ). M3 and M4 hydroxy metabolites resolved at 9 and 9.7 min. From data showing relative abundance of ions, we can suggest that M4 was the major metabolite, whereas M1, M2, and M3 were formed in lesser amounts in HLM incubations. An identical metabolite formation pattern was observed after incubation of 1␣,25(OH) 2 D 3 with human rCYP3A4 Supersomes. No metabolite formation was detected in reaction mixtures without substrate, NADPH, or microsomes.
Results

Metabolism
In contrast, incubation of 1␣,25(OH) 2 D 3 with hepatic microsomes from vehicle-or prednisone-treated mice yielded one major metabolite at 8.9 min (M5) in addition to 1␣,23S,25(OH) 3 D 3 (M1) and 1␣,24R,25(OH) 3 D 3 (M2) as minor metabolites (Fig. 1B) . Similar to
MODULATION OF CYP3A-MEDIATED BIOTRANSFORMATION OF VITAMIN D 3
at ASPET Journals on November 6, 2017 dmd.aspetjournals.org the metabolite profile determined in HLM, dexamethasone-treated mice yielded four metabolites, M1 to M4. However, unlike HLM, M4 was a minor metabolite, whereas, M1, M2, and M3 were the major metabolites formed in the hepatic microsomes prepared from dexamethasone-treated mice.
Effect of Treatment with Glucocorticoids on 1␣,25(OH) 2 D 3 Metabolism. To investigate the effects of treatment with glucocorticoids, experiments were performed with hepatic microsomes prepared from male CD-1 mice treated with vehicle, dexamethasone, or prednisone. The formation of 1␣,23S,25(OH) 3 D 3 (M1) and 1␣,24R,25(OH) 3 D 3 (M2) was significantly stimulated (43-and 17-fold, respectively) in dexamethasone-treated mice compared with the vehicle-treated group (Fig. 2A) . Metabolites M3 and M4 were detectable only in hepatic microsomes from dexamethasone-treated mice but not in vehicle-or prednisonetreated mice (Fig. 2B) . In contrast, treatment with prednisone led to very little or no change in the formation of M1 and M2 metabolites ( Fig. 2A) and a marginal increase in M5 formation compared with vehicle-treated mice (Fig. 2C ). In the substrate-depletion study, there was a 70% greater loss of 1␣,25(OH) 2 D 3 after incubation with hepatic microsomes from dexamethasone-treated mice compared with vehicle-treated mice. In contrast, the amount of 1␣,25(OH) 2 D 3 remained the same after incubation with hepatic microsomes from prednisone-or vehicle-treated mice (Fig. 3) . Table 1 . To compare the metabolic efficiency of microsomes prepared from vehicle-, prednisone-, or dexamethasone-treated mice, the rates of formation of the M1 and M2 were examined. The V max value for M2 formation was significantly higher in dexamethasone-treated mice and marginally increased in prednisone-treated mice compared with vehicle-treated mice (Table 1) . In dexamethasone-treated mice, K m values for M1, M2, and M4 formation are low and comparable, which indicates that these products are predominantly formed at lower concentrations of 1␣,25(OH) 2 D 3 . M4, the most abundant metabolite formed in HLM, has the lowest K m value (7.6 Ϯ 0.2 M). This suggests that even at lower concentrations of 1␣,25(OH) 2 D 3 , formation of M4 will be preferred. Due to lack of availability of authentic standards, V max values for M3, M4, and M5 could not be determined.
P450 Chemical Inhibition Studies. The contribution of individual P450 in 1␣,25(OH) 2 D 3 biotransformation was assessed using chemical inhibitors that selectively targeted P450 isoforms. P450 inhibition studies were performed using pooled hepatic microsomes prepared at ASPET Journals on November 6, 2017 dmd.aspetjournals.org from vehicle-, dexamethasone-, or prednisone-treated mice. We used nine inhibitors of P450 enzymes: ketoconazole (CYP3A), SKF 525A (broad spectrum P450 inhibitor), furafylline (CYP1A2), ␣-naphthoflavone (CYP1A1), sulfaphenazole (CYP2C), quinine (CYP2D), diethyldithiocarbamate (CYP2E), 8-methoxypsoralen (CYP2A), and orphenadrine (CYP2B). The results of the chemical inhibition studies showed that ketoconazole at 1 M inhibited the formation of hydroxy metabolites of 1␣,25(OH) 2 D 3 by ϳ90 to 100% in MLM (Fig. 4) . Comparable inhibition was achieved after incubation with broadspectrum P450 inhibitor SKF 525A. Other P450 inhibitors showed little or no inhibition. Ketoconazole-mediated CYP3A inhibition was observed for the formation of M5 in vehicle-or prednisone-treated mice and for M1, M2, and M3 in dexamethasone-treated mice. The inhibitory effect of ketoconazole on 1␣,25(OH) 2 D 3 biotransformation in MLM was dose-dependent over a concentration range of 0.1 to 10 M (data not shown).
Induction of CYP3A Isoforms and Triazolam Hydroxylation Assay. CYP3A protein levels and marker activity were measured in individual mouse hepatic microsomes. Hepatic CYP3A protein levels were significantly increased after intraperitoneal treatment of adult male CD-1 mice with dexamethasone. An antibody against mouse CYP3A isoforms (CYP3A11, CYP3A16, CYP3A41, CYP3A44, and CYP3A25) was used to detect two protein bands in the immunoblot. The upper band, which was detected in control and treated samples, was used to determine the relative CYP3A protein level. Relative CYP3A protein levels were increased by approximately 53-and 2-fold in liver microsomes from dexamethasone-and prednisonetreated mice, respectively, compared with the vehicle-treated group (Fig. 5A) . Likewise, the formation of 1Ј-hydroxy triazolam and 4-hydroxy triazolam from triazolam, a CYP3A marker activity, was markedly increased in hepatic microsomes from dexamethasone-treated mice, compared with vehicle-treated and prednisone-treated mice (Fig. 5B) .
In Vitro Inhibition of 1␣,25(OH) 2 D 3 Catabolism by Drug Interactions. Pooled HLM were coincubated with 1␣,25(OH) 2 D 3 and the drugs listed below to evaluate their inhibitory potential to cause vitamin D 3 -drug interactions. Drugs used in the present study were those used as anticancer agents (ketoconazole, tamoxifen, docetaxel, and paclitaxel), antivirals (ritonavir), and anti-infectives (clarithromycin, chloramphenicol, troleandomycin). Results from the initial single concentration study suggest that ketoconazole (1 M), docetaxel (1.24 M), and ritonavir (10 M) are the strongest inhibitors of 1␣,25(OH) 2 D 3 catabolism, showing ϳ95 to 100% inhibition (Fig. 6,  A and B) . Other drugs used in our study inhibited the formation of hydroxy metabolites by ϳ40 to 90%. The inhibitory effect of these drugs was further characterized by determining IC 50 values using nonlinear regression analysis. A summary of IC 50 values for the formation of all four metabolites of 1␣,25(OH) 2 D 3 in HLM are shown in Table 2 . Analysis of IC 50 values indicates that ritonavir is the most potent inhibitor of M1 to M4 metabolite formation, followed by ketoconazole and docetaxel. Similar inhibitory effects of these drugs were also observed on triazolam hydroxylation in HLM (Fig. 6C ) and human rCYP3A4 (data not shown). Discussion 1␣,25(OH) 2 D 3 , the active metabolite and the most potent natural analog of vitamin D 3 , is an autocrine and paracrine regulator of multiple physiological functions, which include maintenance of calcium and phosphate levels, bone mineralization, cell proliferation and differentiation, inflammation, and immunity (Holick, 2005) . Thus, 1␣,25(OH) 2 D 3 is a potential candidate for the treatment and prevention of diseases such as rickets/osteomalacia, cancer, and immune disorders (e.g., autoimmune diseases, AIDS-related opportunistic infections). Typically, in mammals, P450-mediated oxidative metabolism of 1␣,25(OH) 2 D 3 is considered as a vital step in its deactivation (Prosser and Jones, 2004) . Although CYP24A1-mediated renal metabolism of 1␣,25(OH) 2 D 3 is well studied, hepatic biotransformation of 1␣,25(OH) 2 D 3 in humans and rodents is not well characterized. In the present study, we investigated the microsomal biotransformation of 1␣,25(OH) 2 D 3 in MLM and HLM and in human rCYP3A4, and we determined the effects of commonly used drugs on the CYP3A-mediated metabolism of 1␣,25(OH) 2 D 3 .
The results from our study show that 1␣,25(OH) 2 D 3 was metabolized to four metabolites in HLM and rCYP3A4 Supersomes (Fig. 7) . Gupta et al. (2004 Gupta et al. ( , 2005 showed that 24-and 25-hydroxylation of 1␣(OH)D 3 , a clinically important analog of vitamin D 3 , are catalyzed by CYP3A4 in a stereospecific manner. In kidney, CYP24A1-mediated metabolism of 1␣,25(OH) 2 D 3 yields both C-23-and C-24-hydroxylated products. From both careful examination of relative retention time and observation of additional multiple reaction monitoring transitions, it is clear that M3 and M5 are two different metabolites with the same molecular weight. Although the chemical identity of the metabolite M5 of 1␣,25(OH) 2 D 3 could not be determined, potential candidates include a hydroxylation product of the aliphatic side chain at C-22 or hydroxylation of methyl group at C-21. For example, rCYP3A4 hydroxylates at the C-22 position of ursodeoxycholic acid, a steroidal structure with aliphatic side chain (Bodin et al., 2005) . Relative contributions of individual P450 enzymes to the hepatic biotransformation of 1␣,25(OH) 2 D 3 in mice was studied using a panel of selective P450 chemical inhibitors. Ketoconazole, used at low concentrations selective for CYP3A isoforms (Baldwin et al., 1995) , inhibited the formation of all the five metabolites in MLM and HLM.
It appears that metabolites M1 to M4 emerged at the expense of M5 after treatment with dexamethasone. Because there are six different CYP3A isoforms (CYP3A11, CYP3A13, CYP3A16, CYP3A25, CYP3A41, and CYP3A44) expressed in MLM, it is plausible that treatment with dexamethasone led to induction of isoforms, which predominantly catalyze the formation of M1 to M4 but not M5. In addition, identical metabolic profiles in rCYP3A4 Supersomes and HLM indicate that CYP3A isoforms are primarily responsible for the hepatic microsomal biotransformation of 1␣,25(OH) 2 D 3 . Previously, it has been shown that mitochondrial CYP24A1 is one of the major enzymes involved in the biotransformation of 1␣,25(OH) 2 D 3 in kidney (Prosser and Jones, 2004) ; however, this does not apply to the liver and intestine. CYP3A4 enzyme constitutes approximately 40 and 80% of the total P450 enzymes in human liver and intestine, respectively (Paine et al., 2006) , whereas mitochondrial CYP24A1 has low or undetectable hepatic and intestinal expression in humans and rodents (Komuro et al., 1999; Cheng et al., 2003; Xu et al., 2006) . In contrast to CYP3A, mitochondrial CYP24A1 is also less inducible by therapeutic or environmental agents (Zhou et al., 2006) , and not many potent inhibitors are known. Thus, based on relative abundance of CYP24A1 and CYP3A4 in human liver and their induction or inhibition potential, it is unlikely that CYP24A1 has any significant role in the hepatic biotransformation of 1␣,25(OH) 2 D 3 .
Metabolite formation pattern in our study is similar to the one report we found of 1␣,25(OH) 2 D 3 biotransformation in HLM (Xu et al., 2006) , which also concluded that hepatic metabolism of Differences between treatment groups were compared using one-way analysis of variance (parametric), followed by the Student Newman Keuls multiple comparison test. ‫,ء‬ significantly different from the control (vehicle-treated) mice with P Ͻ 0.05. #, significantly different from the prednisone-treated mice with P Ͻ 0.05.
TABLE 1
Kinetic parameters for the formation of hydroxy metabolites of 1␣,25-(OH) 2 D 3 in MLM, HLM, and human rCYP3A4 Supersomes
Values represent the mean Ϯ S.E. of triplicate determinations.
Kinetic Parameters Xu et al. (2006) study suggest that 1␣,24R,25(OH) 3 D 3 had also been produced in their incubations, albeit at a much lower extent than we observed, and appeared as a shouldering peak to the adjacent 1␣,24S,25(OH) 3 D 3 peak. Possible explanations for the differences observed in the metabolite profiles and proportions could be incubation conditions (e.g., incubation time, amount of protein) and analytical methodologies (e.g., chromatographic and MS conditions). A species-based difference was also identified between CYP3A-mediated hepatic metabolism of 1␣,25(OH) 2 D 3 in humans and mice. In humans, M4 was the major metabolite, whereas M1, M2, M3, and M5 were the major metabolites in mice. Likewise, CYP24A1-mediated metabolism of 1␣,25(OH) 2 D 3 has been reported to be species-specific. In humans, both the C-23 and C-24 oxidation pathways are present (Beckman et al., 1996) . However, rat and mouse CYP24A1 enzymes show a remarkable preference for C-24 to C-23 hydroxylation (Sakaki et al., 1999 (Sakaki et al., , 2000 . To our knowledge, this is the first (Czock et al., 2005; Beer et al., 2007; Inaba and Pui, 2010) . Results from our study have shown that administration of dexamethasone, but not prednisone, can greatly increase breakdown of 1␣,25(OH) 2 D 3 by CYP3A isoforms in mice, which could potentially lead to diminished biological effects of vitamin D 3 . Although both dexamethasone and prednisone are harmful to bone health, our results could possibly explain the lower incidences of bone disorders after exposure to prednisone (Inaba and Pui, 2010) . In contrast, drugs used to treat cancer (e.g., tamoxifen, taxanes), infectious diseases (e.g., clarithromycin, chloramphenicol), and AIDS (e.g., ritonavir) blocked the hepatic catabolism of the active vitamin D 3 metabolite in vitro, potentially leading to additional chemopreventive effects and maintenance of bone health. Ketoconazole, a drug commonly used in fungal infections and in prostate cancer, potently inhibited 1␣,25(OH) 2 D 3 biotransformation in HLM. It has been previously observed that oral administration of 200 mg of ketoconazole in healthy subjects leads to a peak plasma concentration of 4.5 to 7.5 M (Heel et al., 1982; Gupta et al., 1994) . Likewise, a single dose of ritonavir (600 mg) produced a peak plasma level of 13.1 g/ml or 18 M in healthy volunteers (Ouellet et al., 1998 Dexamethasone induces P450 expression in human and mouse liver via involvement of nuclear receptors such as the pregnane X receptor (PXR) and glucocorticoid receptor (Rushmore and Kong, 2002) . Although prednisone is a glucocorticoid receptor (but not PXR) agonist, there is no report of prednisone-mediated regulation of CYP3A enzymes. This could explain the differential effects of the two glucocorticoids. Moreover, Hashizume et al. (2008) at ASPET Journals on November 6, 2017 dmd.aspetjournals.org homeostasis. Thus, it is critical to recognize that numerous commonly used drugs and herbal supplements are modulators of human and rodent PXR. For example, antiepileptics (e.g., carbamazepine), antineoplastics (e.g., paclitaxel), protease inhibitors (e.g., efavirenz), antihypertensives (e.g., nifedipine), and herbal supplements (e.g., St. John's wort, gingko biloba) are known activators of human PXR (Chang and Waxman, 2006; Yu et al., 2011) . This suggests that exposure to these agents could contribute to the increased catabolism of 1␣,25(OH) 2 D 3 , which leads to altered vitamin D homeostasis. Another point of consideration is that 1␣,25(OH) 2 D 3 also acts as an endogenous regulator of VDR-mediated CYP3A4 expression and therefore may have a role in its own homeostasis and could potentially affect biotransformation of CYP3A substrates. In summary, this is the first report of hepatic biotransformation of 1␣,25(OH) 2 D 3 in mice. Species differences between metabolite profiles derived from mouse and human liver microsomes were observed in the biotransformation of 1␣,25(OH) 2 D 3 . In the present study, CYP3A isoforms were determined to have a major role in the hepatic biotransformation of 1␣,25(OH) 2 D 3 in both species. In addition, this is the first experimental report of stimulation or blockade of 1␣,25(OH) 2 D 3 biotransformation in liver by therapeutic drugs. Dexamethasone, but not prednisone, augments CYP3A-mediated catabolism of 1␣,25(OH) 2 D 3 in mice. In contrast, medications, which are commonly used to treat cancer and AIDS patients, could lead to blockade of active vitamin D 3 catabolism. Overall, therefore, it is reasonable to deduce that treatment regimens used for patients with cancer, AIDS, and inflammatory diseases could affect vitamin D homeostasis.
